SEC Form 4 · accession 0001562180-16-001780
Sagent Pharmaceuticals, Inc. · SGNT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Shlomo Yanai
Director
Period of report
Feb 22, 2016
Accepted (ET)
Feb 23, 2016 · 6:28 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001369786
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | — | Feb 22, 2016 | A | 8,556 | A | — | — | Common Stock | 8,556 | 8,556 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of SGNT common stock.
- F2The restricted stock units vest in four equal annual installments beginning on February 22, 2017. Vested shares will generally be delivered to the reporting person within 30 days following the vesting date.